12:00 AM
 | 
Sep 10, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/7 cls
Addex Therapeutics Ltd. (SIX:ADXN) Wedbush Christopher Marai New Outperform 21% CHF9.20
Marai set a CHF28 target. He believes the "primary value driver" for Addex is a potential near-term partnership for dipraglurant-IR. The immediate-release formulation of a negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) is in Phase II testing to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID). Marai anticipates a partnership by year end or 1H13. He believes peak dipraglurant sales in PD-LID and other indications could exceed $1.5B.
ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC) Maxim Group Jason Kolbert New Buy 23% $3.17
Kolbert set an $18 target on...

Read the full 776 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >